Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Schüll
B
B
Kornek
G V
GV
Scheithauer
W
W
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D006634:Histamine H1 Antagonists; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil